US researchers have revealed(link is external) the identity of molecules on the surface of cancer cells which allow the body’s immune system to identify and destroy them.
The research could lead to a new generation of immunotherapies that are far more effective than those currently in use, that could target a range of cancers.
“This is a huge breakthrough,” said Cancer Research UK’s Dr Sergio Quezada, who works at UCL in London and was not involved in the research.
“The researchers were looking for ‘signatures’ on the surface of cancer cells associated with response to current immunotherapies, but their findings go further than that. They’ve actually discovered molecular motifs that will inform the development of the next generation of therapies,” he added.
The researchers, led by a team at the Memorial Sloan Kettering Cancer Centre in New York, analysed cancer DNA from 64 melanoma patients who had been treated with an immunotherapy drug called ipilimumab, half of whom had responded to the drug.
Ipilimumab works by switching on the body’s immune system to attack their cancer, but – for unknown reasons – it only works effectively in a minority of patients.
“We’ve been using a drug that empirically was found to be quite effective, and yet we didn’t have a detailed understanding of how it was working in people,” said Memorial Sloan Kettering’s Dr Jedd Wolchok.
Having analysed the patients’ cancer DNA, the researchers used sophisticated software to look for genetic mutations in the cancer cells that could predict whether patients had, or hadn’t, responded to the drug.
In doing so, they uncovered a series of genetic mutations in some of the patients that caused the cancer cells to produce short stretches of protein molecules, called peptide antigens, that make cancerous cells visible to immune response.
Tantalisingly, it appears that these mutations cause the antigens to mimic small parts of proteins produced by bacteria and viruses, explaining why they are so effective at triggering the immune response – although the researchers say more research will be needed to confirm this.
The discovery is “big, big news” for immunotherapy researchers says Cancer Research UK’s Dr Quezada. “This is the first time we’ve had an idea of what the immune system actually ‘sees’ on a tumour. Until now, it’s been hot topic of debate,” he said.
The Latest on: Immunotherapies
via Google News
The Latest on: Immunotherapies
- Fate Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conferenceon February 22, 2021 at 1:14 pm
Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer ...
- Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapyon February 19, 2021 at 8:13 pm
Despite great success in cancer immunotherapy, immune checkpoint-targeting drugs are not the most popular weapon in the armory of cancer therapy. Accumulating evidence suggests that the tumor immune ...
- Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with canceron February 19, 2021 at 6:50 am
In this Consensus Statement, members from five working groups or societies provide updated comprehensive recommendations to manage toxicities from cancer immunotherapies in children, adolescents and ...
- Immunocore’s tebentafusp granted Breakthrough Therapy Designation for unresectable or ...on February 19, 2021 at 4:44 am
Immunocore (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of ...
- Immunocore’s tebentafusp granted Breakthrough Therapy Designation for unresectable or metastatic uveal melanoma from FDAon February 19, 2021 at 4:00 am
Immunocore, a late-stage biotechnology company pioneering the development of a novel class of T cell receptor bispecific immunotherapies designed to treat a broad range of diseases, including cancer, ...
- 2021 Szent-Györgyi Prize Awarded to Pioneering Research Duo Who Have Paved the Path to Life-Saving T-Cell Receptor-Based Cancer Immunotherapieson February 18, 2021 at 11:00 am
The National Foundation for Cancer Research (NFCR) announced today that the 2021 Szent-Györgyi Prize for Progress in Cancer Research will ...
- Global Pancreatic Cancer Drugs Market Growth, Size, Share, Industry Report and Forecast 2020-2026on February 18, 2021 at 3:24 am
The global pancreatic cancer drugs market has significant opportunity owing to the emerging drugs in the pipeline for the treatment of pancreatic cancer Several immunotherapies and targeted therapies ...
- Allergy Immunotherapies Market Hit 4,185.89 million by 2027 and to grow at a CAGR of 11.1% from 2020 to 2027on February 17, 2021 at 1:40 pm
Lucrative Regions for Allergy Immunotherapies Market” Allergy immunotherapies market was valued at US$ 1,819.18 million in 2019 and is projected to reach US$ ...
- Elicio Therapeutics Secures a Total of $73 Million in Series B Financingon February 17, 2021 at 5:45 am
Elicio Therapeutics, a private biotechnology company developing a pipeline of potent immunotherapies based on its proprietary lymph node targeting technology, announced the successful completion of ...
- Kineta, Inc.-Developing Novel Immunotherapies to Transform Patients' Liveson February 16, 2021 at 9:00 pm
Dr. Shawn Iadonato, CEO of Kineta, Inc., will discuss the clinical stage biotechnology company committed to developing disruptive life science technologies that address unmet patient needs especially ...
via Bing News